IpiNovyx Bio
We are a drug platform focused on treating autoimmune and inflammatory diseases.
We are a drug platform focused on treating autoimmune and inflammatory diseases.
IpiNovyx Bio is a biotechnology startup that aims to revolutionize the treatment of autoimmune and inflammatory diseases. Established in 2021 and headquartered in the United States, the company is driven by the slogan, "We are a drug platform focused on treating autoimmune and inflammatory diseases." Their innovative approach involves the development of highly selective, ultra potent small molecule therapeutics tailored for this purpose. These breakthrough technologies have the potential to introduce a new paradigm in addressing various autoimmune and complex inflammatory disorders, ultimately offering patients a brighter future.
Notably, the company secured $10.00M in Seed Round investment on 05 October 2021. The investment came from an impressive group of backers including Viva BioInnovator, Alexandria Venture Investments, Generation Ventures, Lilly Ventures, Pathway Bioventures, Patrick Spaulding Ryan Ph.D, Opaleye Management, and Orange Grove Bio. This substantial backing reflects the confidence of industry leaders in the potential of IpiNovyx Bio's pioneering approach to addressing unmet medical needs in the field of autoimmune and inflammatory diseases.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | $10.00M | 8 |
|
05 Oct 2021 |
No recent news or press coverage available for IpiNovyx Bio.
We care about your data, and we'd love to use cookies make your experience better.
